CENGILD MEDICAL |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3 MYR | -3.23% |
|
-.--% | -10.45% |
| Sales 2022 | 64.44M 13.51M 1.08B | Sales 2023 | 70.28M 14.73M 1.18B | Capitalization | 329M 68.97M 5.51B |
|---|---|---|---|---|---|
| Net income 2022 | 9M 1.89M 151M | Net income 2023 | 13M 2.73M 218M | EV / Sales 2022 | 3.98 x |
| Net cash position 2022 | 70.87M 14.86M 1.19B | Net cash position 2023 | 84.1M 17.63M 1.41B | EV / Sales 2023 | 3.48 x |
| P/E ratio 2022 |
27.4
x | P/E ratio 2023 |
24.5
x | Employees | 130 |
| Yield 2022 |
0.93% | Yield 2023 |
1.87% | Free-Float | 30.21% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.23% | ||
| Current month | -1.64% | ||
| 1 month | -1.64% | ||
| 3 months | +1.69% | ||
| 6 months | -13.04% | ||
| Current year | -10.45% |
1 week
0.30
0.32
1 month
0.290.35
Current year
0.280.35
1 year
0.280.46
3 years
0.280.58
5 years
0.280.58
10 years
0.280.58
| Managers | Title | Age | Since |
|---|---|---|---|
Huck Joo Tan
CHM | Chairman | 56 | 02/02/21 |
Siew Kuen Ong
CTO | Chief Tech/Sci/R&D Officer | 56 | 31/12/16 |
| Director/Board Member | 63 | 30/04/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Su Lin Chong
BRD | Director/Board Member | 63 | 03/05/21 |
Huck Joo Tan
CHM | Chairman | 56 | 02/02/21 |
Choo Kai Kua
BRD | Director/Board Member | 64 | 03/05/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 0.3 | -3.23% | 3,368,800 |
| 29/04/24 | 0.31 | -.--% | 887,200 |
| 26/04/24 | 0.31 | +1.64% | 217,000 |
| 25/04/24 | 0.305 | -.--% | 752,800 |
| 24/04/24 | 0.305 | +1.67% | 2,628,500 |
End-of-day quote BURSA MALAYSIA, April 29, 2024
More quotes
Cengild Medical Berhad is a Malaysia-based investment holding company. The Company, through its subsidiary, is a healthcare provider specializing in the diagnosis and treatment of gastrointestinal and liver disease. The Company has around 36,588 sq. ft. medical center, which provides diagnostic and therapeutic facilities with 28 licensed beds, two fully equipped operating theatres, three endoscopy suites, and imaging facilities such as fibro scan, ultrasonography, computerized tomography (CT) scan, fluoroscopy, angiography equipment for endoscopic retrograde cholangiopancreatography (ERCP)s and other procedures. Its medical center's business activities comprise of consultant services and medical management services, which includes nursing services and clinical support services. In addition, it also offers 24-hour outpatient accident and emergency service, health screening, physiotherapy, and histopathology services. Its subsidiaries include Cengild Sdn. Bhd., and Galen Primer Sdn. Bhd.
Calendar
27/05/2024
- Q3 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.45% | 52.41M | |
| -18.46% | 16.57B | |
| +4.50% | 12.4B | |
| +4.98% | 11.69B | |
| +4.26% | 10.24B | |
| -2.91% | 7.76B | |
| +20.21% | 7.17B | |
| +6.45% | 6.74B | |
| +50.68% | 4.65B | |
| -5.12% | 4.25B |
- Stock Market
- Equities
- CENGILD Stock
